In this study the authors investigated ErbB2 expression by immunohistochemistry in 120 HNSCC tissue sections including laryngeal, oral cavity and oropharyngeal squamous cell carcinomas, and evaluated ErbB2 immunostaining using two systems: the conventional scoring system approved by the FDA, which takes into account the degree of membrane staining in >10% of cells, and an H-score-based system, in which an H-score value is obtained for each section by multiplying the intensity score by a proportion score based on the percentage of stained cells. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.